Ivermectin in Treatment of COVID-19

Last updated: June 19, 2020
Sponsor: Zagazig University
Overall Status: Active - Recruiting

Phase

2/3

Condition

Coronavirus

Covid-19

Corona Virus

Treatment

N/A

Clinical Study ID

NCT04445311
ZU-IRB#6151/31-5-2020
  • Ages 18-70
  • All Genders

Study Summary

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Eligibility Criteria

Inclusion

Inclusion Criteria: COVID-19 patients during period of the study more than 18 years old

Exclusion

Exclusion Criteria: refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive anydrug with interaction with ivermectin

Study Design

Total Participants: 100
Study Start date:
May 31, 2020
Estimated Completion Date:
August 15, 2020

Connect with a study center

  • Waheed Shouman

    Zagazig, Sharkia 44519
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.